医学
肺
间质性肺病
肺病
放射科
疾病
病理
内科学
作者
Yiding Bian,Mingming Deng,Qian Gao,Guowu Zhou,Run Tong,Ling Zhao,Min Liu,Jie Sun,Huaping Dai,Felix J.F. Herth,Gang Hou,Chen Wang
出处
期刊:Lung
[Springer Science+Business Media]
日期:2024-06-23
卷期号:202 (5): 615-623
被引量:17
标识
DOI:10.1007/s00408-024-00713-2
摘要
Introduction: Transbronchial lung cryobiopsy (TBLC) is increasingly used to diagnose interstitial lung disease (ILD). The 1.1-mm cryoprobe has recently been available in clinical practice. The diagnostic yield and safety of TBLC using a 1.1-mm cryoprobe need to be confirmed. Methods: A prospective, randomized controlled trial was conducted in patients with suspected ILD and randomly assigned to 1.1-mm and 1.9-mm cryoprobe groups. The primary outcome was the diagnostic yield of multidisciplinary discussion (MDD). Secondary outcomes were sample quality and incidence of complications. The tension and stress effects during TBLC onto the target lobe caused by 1.1-mm, 1.9-mm, and 2.4 mm cryoprobes were also evaluated using finite element analysis. Results:A total of 224 patients were enrolled. No significant differences were observed in the diagnostic yield (80.4% vs. 79.5%, p=0.845) and sample quality scores (5.73±0.64 vs. 5.66±0.77; p=0.324) between the 1.9-mm cryoprobe group and 1.1-mm cryoprobe group. The average surface areas of samples in 1.1-mm cryoprobe group were smaller, while no difference in sample weights was observed. A decreased incidence of moderate bleeding was found in the 1.1-mm cryoprobe group (17.0% vs. 6.2%, p=0.027), while the incidence of pneumothorax was higher in the 1.1-mm cryoprobe group but did not reach statistical significance (1.8% vs. 7.1%, p=0.070). In finite element analysis, the 1.1-mm cryoprobe required the largest tension and produced the largest stress. Conclusion:Compared with a 1.9-mm cryoprobe, there was no difference in specimen quality or diagnostic rate but smaller sample size with a 1.1-mm cryoprobe. Trail registration: clinicaltrials.gov identifier NCT04047667; registered August 4, 2019
科研通智能强力驱动
Strongly Powered by AbleSci AI